Metabolic syndrome and endometrial carcinoma

American Journal of Epidemiology

Volumn 171, Issue 8, 2010, Pages 892-902

  Bjørge, Tone ^a,b   Stocks, Tanja ^c   Lukanova, Annekatrin ^d   Tretli, Steinar ^e   Selmer, Randi ^b   Manjer, Jonas ^f   Rapp, Kilian ^g   Ulmer, Hanno ^h   Almquist, Martin ^f   Concin, Hans ⁱ   Hallmans, Göran ^c   Jonsson, Hkan ^c   Stattin, Pär ^c   Engeland, Anders ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e CANCER REGISTRY OF NORWAY   (Norway)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF ULM   (Germany)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

Author keywords

Cohort studies; Endometrial neoplasms; Metabolic syndrome X

Indexed keywords

BODY MASS; CANCER; CARCINOGEN; COHORT ANALYSIS; GLUCOSE; HEALTH RISK; METABOLISM; OBESITY; REGRESSION ANALYSIS; WOMENS HEALTH;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOMETRIUM CARCINOMA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AUSTRIA; BODY MASS INDEX; CAUSE OF DEATH; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; METABOLIC SYNDROME X; MIDDLE AGED; NORWAY; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS; SWEDEN;

AUSTRIA; NORWAY; SWEDEN;

EID: 77950848588     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq006     Document Type: Article

References (53)

1. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. The metabolic syndrome: A concept hard to define. Arch Med Res. 2005;36(3):223-231. (Pubitemid 40755135)
2. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066-1076. (Pubitemid 38668985)
3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004; 27(10):2444-2449. (Pubitemid 39281399)
4. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: Time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28(9):2289-2304. (Pubitemid 41242486)
5. Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond). 2008;32(2):304-314. (Pubitemid 351271779)
6. Eisenmann JC. On the use of a continuous metabolic syndrome score in pediatric research [electronic article]. Cardiovasc Diabetol. 2008;7:17.
7. Franks PW, Ekelund U, Brage S, et al. Does the association of habitual physical activity with the metabolic syndrome differ by level of cardiorespiratory fitness? Diabetes Care. 2004; 27(5):1187-1193. (Pubitemid 38579788)
8. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006;169(5):1505-1522. (Pubitemid 351181984)
9. Lund HÅheim L, Wisløff TF, Holme I, et al. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006; 164(8):769-774. (Pubitemid 44522081)
10. Stürmer T, Buring JE, Lee IM, et al. Metabolic abnormalities and risk for colorectal cancer in the Physicians' Health Study. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2391-2397. (Pubitemid 46048295)
11. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
12. Bjørge T, Engeland A, Tretli S, et al. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007;120(2):378-383. (Pubitemid 44956850)
13. Bergström A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91(3): 421-430. (Pubitemid 32049639)
14. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003; 104(6):669-676. (Pubitemid 36418502)
15. Weiderpass E, Persson I, Adami HO, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control. 2000;11(2):185-192. (Pubitemid 30088399)
16. Lindemann K, Vatten LJ, Ellstrøm-Engh M, et al. Body mass, diabetes and smoking, and endometrial cancer risk: A followup study. Br J Cancer. 2008;98(9):1582-1585. (Pubitemid 351652323)
17. Cust AE, Kaaks R, Friedenreich C, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007; 14(3):755-767. (Pubitemid 350074064)
18. Stocks T, Borena W, Strohmaier S, et al. Cohort profile: The Metabolic Syndrome and Cancer Project (Me-Can). Int J Epidemiol. 2009;Apr 20 [Epub ahead of print].
19. Stocks T. Metabolic Factors and Cancer Risk. Prospective Studies of Prostate Cancer, Colorectal Cancer, and Cancer Overall [thesis]. UmeÅ, Sweden: Department of Surgical and Perioperative Sciences, Urology and Andrology, UmeÅ University; 2009.
20. Naess O, Søgaard AJ, Arnesen E, et al. Cohort profile: Cohort of Norway (CONOR). Int J Epidemiol. 2008;37(3):481-485. (Pubitemid 351804000)
21. Tverdal A. Systolic and diastolic blood pressures as predictors of coronary heart disease in middle aged Norwegian men. Br Med J (Clin Res Ed). 1987;294(6573):671-673. (Pubitemid 17041961)
22. National Health Screening Service. The Cardiovascular Disease Study in Norwegian Counties. Results From Second Screening. Oslo, Norway: National Health Screening Service; 1988.
23. Stensvold I, Tverdal A, Urdal P, et al. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993;307(6915):1318-1322. (Pubitemid 23337748)
24. Silverberg SG, Kurman RJ, Nogales F. Tumours of the uterine corpus. Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:221-232.
25. Eurostat. METADATA: European Shortlist for Causes of Death, 1998. Brussels, Belgium: European Commission; 2009. (http://ec.europa.eu/eurostat/ ramon/nomenclatures/ index.cfm?TargetUrl=LST-NOM-DTL&StrNom=COD-1998). (Accessed May 30, 2009).
26. Cox DR, Oakes D. Analysis of Survival Data. London, United Kingdom: Chapman and Hall Ltd; 1984.
27. SPSS, Inc. SPSS for Windows. Release 15.0.1. Chicago, IL: SPSS, Inc; 2006.
28. Barlow L,Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol. 2009;48(1):27-33.
29. Cancer Registry of Norway. Cancer in Norway 2006. Oslo, Norway: Cancer Registry of Norway; 2007.
30. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49(5):945-952.
31. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
32. Kahn R. Metabolic syndrome-what is the clinical usefulness? Lancet. 2008;371(9628):1892-1893.
33. Unwin N. The metabolic syndrome. J R Soc Med. 2006;99(9): 457-462. (Pubitemid 44549900)
34. Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(4):921-929. (Pubitemid 351536424)
35. Weiderpass E, Brismar K, Bellocco R, et al. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer. 2003;89(9): 1697-1704. (Pubitemid 37464142)
36. Kalseth B, Backe B. Hysterectomies in Norway [in Norwegian]. In: Kalseth B, Røttingen JA, eds. Praksis og Kvalitet i Sykehus. Trondheim/Oslo, Norway: SINTEF/HELTEF; 2002: 101-132.
37. Lundholm C, Forsgren C, Johansson AL, et al. Hysterectomy on benign indications in Sweden 1987-2003: A nationwide trend analysis. Acta Obstet Gynecol Scand. 2009;88(1):52-58.
38. Wu JM,Wechter ME, Geller EJ, et al. Hysterectomy rates in the United States, 2003. Obstet Gynecol. 2007;110(5):1091-1095.
39. Lindgren AM, Nissinen AM, Tuomilehto JO, et al. Cancer pattern among hypertensive patients in North Karelia, Finland. J Hum Hypertens. 2005;19(5):373-379.
40. Soler M, Chatenoud L, Negri E, et al. Hypertension and hormone-related neoplasms in women. Hypertension. 1999; 34(2):320-325. (Pubitemid 29409235)
41. Strasak AM, Pfeiffer RM, Brant LJ, et al. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: A prospective 19-year follow-up study. Ann Oncol. 2009;20(6):1113-1120.
42. Cust AE, Allen NE, Rinaldi S, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;120(12):2656-2664. (Pubitemid 46651288)
43. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer. 2004;108(2):262-268. (Pubitemid 37541781)
44. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591. (Pubitemid 39025053)
45. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24(2):68-72.
46. Warburg O. On the origin of cancer cells. Science. 1956; 123(3191):309-314.
47. Goldman NA, Katz EB, Glenn AS, et al. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol. 2006;19(11):1429-1436.
48. Shibata K, Kajiyama H, Ino K, et al. P-LAP/IRAP-induced cell proliferation and glucose uptake in endometrial carcinoma cells via insulin receptor signaling [electronic article]. BMC Cancer. 2007;7:15. (Pubitemid 46210978)
49. Valko M, Izakovic M, Mazur M, et al. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266(1-2):37-56. (Pubitemid 39562306)
50. Schleicher ED,Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997; 99(3):457-468. (Pubitemid 27414803)
51. Uribarri J, Cai W, Sandu O, et al. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci. 2005;1043:461-466. (Pubitemid 41123934)
52. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251(2):87-101. (Pubitemid 34146691)
53. Hamet P. Cancer and hypertension: A potential for crosstalk? J Hypertens. 1997;15(12):1573-1577. (Pubitemid 28029651)